First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Top Cited Papers
- 19 November 2020
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 383 (21), 2018-2029
- https://doi.org/10.1056/nejmoa2027187
Abstract
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear.Funding Information
- Pfizer (N/A)
This publication has 28 references indexed in Scilit:
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose AlectinibJournal of Thoracic Oncology, 2015
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsCancer Cell, 2015
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor AlectinibClinical Cancer Research, 2014
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsJournal of Medicinal Chemistry, 2014
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain MetastasesCurrent Oncology, 2013
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007